drug-delivery

For a new drug to work in the human body, it must make its way to the exact cell type where it's needed and then, in many cases, get inside the cells.

Short-lived radioactive isotopes, or radioisotopes, can image tumors or inflict high levels of cellular damage to them.

Nature Communications, Published online: 14 August 2026; doi:10.1038/s41467-026-76849-x Cytosolic delivery of therapeutic proteins remains a challenge in drug delivery. Here, the authors report the discovery and characterisation of a permeable encapsulin based protein nanocage and use it to develop a modular nanocarrier for cytosolic protein delivery.

Targeted radionuclide therapy has great potential for developing cancer treatments. One approach is to combine a radioisotope with a nanoparticle that transports it to the tumor. Scientists produced a layered nanoparticle that strongly binds the radioisotope to itself and delivers it to the target.

Targeted radionuclide therapy has great potential for developing cancer treatments. One approach is to combine a radioisotope with a nanoparticle that transports it to the tumor. Scientists produced a layered nanoparticle that strongly binds the radioisotope to itself and delivers it to the target.

Researchers publishing in ACS' Journal of Medicinal Chemistry have developed a new cancer therapy that is kept "locked" unless it finds itself within a tumor cell. In mice, the treatment significantly reduced tumor size without accumulating in the liver, which suggests adverse exposures could be reduced and treatment safety improved.

The use of nanoparticles in drug delivery offers key advantages: They can enable targeted drug delivery, protect active ingredients from premature degradation, extend their duration of action in the body and reduce side effects.

Rice University engineers have developed a new strategy for controlling how therapeutic peptides are released from gelatin-based materials, a step that could make the small but powerful molecules more useful in tissue engineering and drug delivery.

Pulmonary fibrosis (PF) requires delivery strategies that improve drug residence within lung tissue while limiting systemic exposure. Herein, roxadustat-loaded silk fibroin nanoparticles (RXS-SKNPs) were developed and coated with gelatin (GT) to produce an MMP-2-responsive pulmonary delivery platform. RXS-SKNPs were prepared by desolvation-assisted nanoprecipitation, followed by GT coating via el…

Nature Communications, Published online: 30 July 2026; doi:10.1038/s41467-026-76188-x Targeted lung delivery of therapeutics is critical for various respiratory diseases. Here, authors develop heteropolypeptide-decorated nanoparticles that exhibit lung targeting through in situ erythrocyte hitchhiking in a sequence-dependent manner, which is further used for the treatment of acute lung injury.

The encapsulation efficiency (%EE), used here as a consistently reported operational proxy for encapsulation performance in literature-derived datasets, in niosomal drug delivery systems has been analyzed using predictive modeling. However, these methods are hardly able to support intervention-oriented reasoning adequately. Therefore, the present study adopts a developed causal discovery framewor…